-
1
-
-
0033842027
-
Interactions between insulin resistance and insulin secretion in the development of glucose intolerance
-
Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000; 106: 329-33.
-
(2000)
J Clin Invest
, vol.106
, pp. 329-333
-
-
Cavaghan, M.K.1
Ehrmann, D.A.2
Polonsky, K.S.3
-
2
-
-
0035856943
-
Diabetes mellitus and genetically programmed defects in [beta]-cell function
-
Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in [beta]-cell function. Nature 2001; 414: 788-91.
-
(2001)
Nature
, vol.414
, pp. 788-791
-
-
Bell, G.I.1
Polonsky, K.S.2
-
3
-
-
0038707331
-
Selective SS-cell loss and---cell expansion in patients with type 2 diabetes mellitus in Korea
-
Yoon KH, Ko SH, Cho JH, et al. Selective SS-cell loss and---cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88: 2300-8.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 2300-2308
-
-
Yoon, K.H.1
Ko, S.H.2
Cho, J.H.3
-
4
-
-
33845866857
-
Inflammation and metabolic disorders
-
Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
-
(2006)
Nature
, vol.444
, pp. 860-867
-
-
Hotamisligil, G.S.1
-
6
-
-
0030061922
-
IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-ii-and obesity-induced insulin resistance
-
Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-ii-and obesity-induced insulin resistance. Science 1996; 271: 665-70.
-
(1996)
Science
, vol.271
, pp. 665-670
-
-
Hotamisligil, G.S.1
Peraldi, P.2
Budavari, A.3
-
8
-
-
70449394029
-
Pancreatic islet inflammation in type 2 diabetes: From yyyand aaacell compensation to dysfunction
-
Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: From yyyand aaacell compensation to dysfunction. Arch Physiol Biochem 2009; 115: 240-7.
-
(2009)
Arch Physiol Biochem
, vol.115
, pp. 240-247
-
-
Ehses, J.A.1
Ellingsgaard, H.2
Boni-Schnetzler, M.3
Donath, M.Y.4
-
9
-
-
33748331194
-
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes
-
Mu J, Woods J, Zhou Y-P, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-1704.
-
(2006)
Diabetes
, vol.55
, pp. 1695-1704
-
-
Mu, J.1
Woods, J.2
Zhou, Y-P.3
-
10
-
-
0033513455
-
Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
-
Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-6.
-
(1999)
Diabetes
, vol.48
, pp. 2270-2276
-
-
Xu, G.1
Stoffers, D.A.2
Habener, J.F.3
Bonner-Weir, S.4
-
11
-
-
57349099271
-
Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-Hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-Oxopentyl)-N-[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-l-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes
-
Cheng Q, Law PK, de Gasparo M, Leung PS. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-Hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-Oxopentyl)-N-[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-l-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J Pharmacol Exp Ther 2008; 327: 683-91.
-
(2008)
J Pharmacol Exp Ther
, vol.327
, pp. 683-691
-
-
Cheng, Q.1
Law, P.K.2
de Gasparo, M.3
Leung, P.S.4
-
12
-
-
0036583164
-
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
-
Ahrén B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-75.
-
(2002)
Diabetes Care
, vol.25
, pp. 869-875
-
-
Ahrén, B.1
Simonsson, E.2
Larsson, H.3
-
13
-
-
37149006184
-
Management of type 2 diabetes in treatment-naive elderly patients
-
Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients. Diabetes Care 2007; 30: 3017-22.
-
(2007)
Diabetes Care
, vol.30
, pp. 3017-3022
-
-
Pratley, R.E.1
Rosenstock, J.2
Pi-Sunyer, F.X.3
-
14
-
-
37349073397
-
8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes
-
Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007; 50: 6450-53.
-
(2007)
J Med Chem
, vol.50
, pp. 6450-6453
-
-
Eckhardt, M.1
Langkopf, E.2
Mark, M.3
-
15
-
-
59649105751
-
Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356[(R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models
-
Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356[(R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009; 328: 556-3.
-
(2009)
J Pharmacol Exp Ther
, vol.328
, pp. 553-556
-
-
Thomas, L.1
Tadayyon, M.2
Mark, M.3
-
16
-
-
41149118550
-
(R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
-
Thomas L, Eckhardt M, Langkopf E, et al.(R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008; 325: 175-182.
-
(2008)
J Pharmacol Exp Ther
, vol.325
, pp. 175-182
-
-
Thomas, L.1
Eckhardt, M.2
Langkopf, E.3
-
17
-
-
0026761361
-
Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter
-
Wells RG, Pajor AM, Kanai Y, et al. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol Renal Physiol 1992; 263: F459-F65.
-
(1992)
Am J Physiol Renal Physiol
, vol.263
-
-
Wells, R.G.1
Pajor, A.M.2
Kanai, Y.3
-
18
-
-
0028044629
-
The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for Dglucose
-
Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for Dglucose. J Clin Invest 1994; 93: 397-404.
-
(1994)
J Clin Invest
, vol.93
, pp. 397-404
-
-
Kanai, Y.1
Lee, W.S.2
You, G.3
Brown, D.4
Hediger, M.A.5
-
19
-
-
52649083832
-
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
-
Fujimori Y, Katsuno K, Nakashima I, et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268-76.
-
(2008)
J Pharmacol Exp Ther
, vol.327
, pp. 268-276
-
-
Fujimori, Y.1
Katsuno, K.2
Nakashima, I.3
-
20
-
-
33845873376
-
Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level
-
Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007; 320: 323-30.
-
(2007)
J Pharmacol Exp Ther
, vol.320
, pp. 323-330
-
-
Katsuno, K.1
Fujimori, Y.2
Takemura, Y.3
-
21
-
-
67349275999
-
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
-
Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-19.
-
(2009)
Clin Pharmacol Ther
, vol.85
, pp. 513-519
-
-
Komoroski, B.1
Vachharajani, N.2
Feng, Y.3
-
22
-
-
33746588255
-
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy
-
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006; 29: 1963-72.
-
(2006)
Diabetes Care
, vol.29
, pp. 1963-1972
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
-
23
-
-
0032983666
-
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus
-
for the UKPDSG
-
Turner RC, Cull CA, Frighi V, Holman RR, for the UKPDSG. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. JAMA 1999; 281: 2005-12.
-
(1999)
JAMA
, vol.281
, pp. 2005-2012
-
-
Turner, R.C.1
Cull, C.A.2
Frighi, V.3
Holman, R.R.4
-
24
-
-
78650720971
-
Initial combination therapy for type 2 diabetes mellitus: Is it ready for prime time?
-
Zinman B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? Am J Med 2011; 124: S19-S34.
-
(2011)
Am J Med
, vol.124
-
-
Zinman, B.1
-
25
-
-
84858212683
-
Sodium glucose co transporter 2 (SGLT2) inhibitors: A new sword for the treatment of type 2 diabetes mellitus
-
Rajesh R, Naren P, Vidyasagar S, et al. Sodium glucose co transporter 2 (SGLT2) inhibitors: a new sword for the treatment of type 2 diabetes mellitus. Int J Pharm Sci Res 2010; 1: 139-47.
-
(2010)
Int J Pharm Sci Res
, vol.1
, pp. 139-147
-
-
Rajesh, R.1
Naren, P.2
Vidyasagar, S.3
-
26
-
-
78649691630
-
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study
-
Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 65-74.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 65-74
-
-
Taskinen, M.R.1
Rosenstock, J.2
Tamminen, I.3
-
27
-
-
79953044464
-
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes
-
Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabetic Med 2010; 27: 1409-19.
-
(2010)
Diabetic Med
, vol.27
, pp. 1409-1419
-
-
Forst, T.1
Uhlig-Laske, B.2
Ring, A.3
-
28
-
-
33644781780
-
Angiotensin II type 1 receptor blockade improves 11-cell function and glucose tolerance in a mouse model of type 2 diabetes
-
Chu KY, Lau T, Carlsson P-O, Leung PS. Angiotensin II type 1 receptor blockade improves 11-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 2006; 55: 367-74.
-
(2006)
Diabetes
, vol.55
, pp. 367-374
-
-
Chu, K.Y.1
Lau, T.2
Carlsson, P-O.3
Leung, P.S.4
-
29
-
-
0030942255
-
Proliferation and differentiation in the human fetal endocrine pancreas
-
Bouwens L, Lu WG, De Krijger R. Proliferation and differentiation in the human fetal endocrine pancreas. Diabetologia 1997; 40: 7.
-
(1997)
Diabetologia
, vol.40
, pp. 7
-
-
Bouwens, L.1
Lu, W.G.2
de Krijger, R.3
-
30
-
-
69549098032
-
IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat
-
Ehses JA, Lacraz G, Giroix MH, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA 2009: 106(33): 13998-4003.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, Issue.33
, pp. 13998-14003
-
-
Ehses, J.A.1
Lacraz, G.2
Giroix, M.H.3
-
31
-
-
33748306069
-
Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat
-
Homo-Delarche F, Calderari S, Irminger J-C, et al. Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes 2006; 55: 1625-33.
-
(2006)
Diabetes
, vol.55
, pp. 1625-1633
-
-
Homo-Delarche, F.1
Calderari, S.2
Irminger, J-C.3
-
32
-
-
1542374750
-
Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets
-
Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-8.
-
(2004)
Diabetologia
, vol.47
, pp. 240-248
-
-
Lau, T.1
Carlsson, P.O.2
Leung, P.S.3
-
33
-
-
0036724346
-
Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in highrisk Hispanic women
-
Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in highrisk Hispanic women. Diabetes 2002; 51: 2796-2803.
-
(2002)
Diabetes
, vol.51
, pp. 2796-2803
-
-
Buchanan, T.A.1
Xiang, A.H.2
Peters, R.K.3
-
34
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
Group UPDSU. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998; 352: 837-53.
-
(1998)
The Lancet
, vol.352
, pp. 837-853
-
-
Group, U.P.D.S.U.1
-
35
-
-
52249109319
-
New combination treatments in the management of diabetes: Focus on sitagliptin-metformin
-
Green J, Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag 2008; 4: 9.
-
(2008)
Vasc Health Risk Manag
, vol.4
, pp. 9
-
-
Green, J.1
Feinglos, M.2
-
36
-
-
77956744479
-
Effects of combined ezetimibe and simvastatin therapy as compared to simvastatin alone in patients with type 2 diabetes: A prospective randomized double-blind clinical trial
-
Ruggenenti P, Cattaneo D, Rota S, et al. Effects of combined ezetimibe and simvastatin therapy as compared to simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care 2010: 33(9): 1954-6.
-
(2010)
Diabetes Care
, vol.33
, Issue.9
, pp. 1954-1956
-
-
Ruggenenti, P.1
Cattaneo, D.2
Rota, S.3
-
37
-
-
65449135058
-
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: A 54-week study
-
Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009; 25: 569-83.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 569-583
-
-
Williams-Herman, D.1
Johnson, J.2
Teng, R.3
-
38
-
-
84866529981
-
The DPP-4 inhibitor linagliptin significantly improves insulin sensitivity in diet induced obese mice
-
Kern M KN, Klein T, Mark M, Blüher M. The DPP-4 inhibitor linagliptin significantly improves insulin sensitivity in diet induced obese mice. Diabetes 2010; (Suppl 1) 59: A577.
-
(2010)
Diabetes
, vol.59
, Issue.SUPPL. 1
-
-
Kern, M.K.N.1
Klein, T.2
Mark, M.3
Blüher, M.4
-
39
-
-
71949118923
-
Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I
-
Boni-Schnetzler M, Boller S, Debray S, et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009; 150: 5218-29.
-
(2009)
Endocrinology
, vol.150
, pp. 5218-5229
-
-
Boni-Schnetzler, M.1
Boller, S.2
Debray, S.3
-
40
-
-
0036738398
-
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
-
Maedler K, Sergeev P, Ris F, et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 10.
-
(2002)
J Clin Invest
, vol.110
, pp. 10
-
-
Maedler, K.1
Sergeev, P.2
Ris, F.3
-
41
-
-
0043168062
-
Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells
-
Vives-Pi M, Somoza N, FernÁNdez-Alvarez J, et al. Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells. Clin Exp Immunol 2003; 133: 208-18.
-
(2003)
Clin Exp Immunol
, vol.133
, pp. 208-218
-
-
Vives-Pi, M.1
Somoza, N.2
FernÁNdez-Alvarez, J.3
-
42
-
-
44849125877
-
Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways
-
De Filippo K, Henderson RB, Laschinger M, Hogg N. Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. J Immunol 2008; 180: 4308-15.
-
(2008)
J Immunol
, vol.180
, pp. 4308-4315
-
-
de Filippo, K.1
Henderson, R.B.2
Laschinger, M.3
Hogg, N.4
-
43
-
-
79952404360
-
SGLT2 deletion improves glucose homeostasis and preserves pancreatic-cell function
-
Jurczak MJ, Lee H-Y, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic-cell function. Diabetes 2011; 60: 890-8.
-
(2011)
Diabetes
, vol.60
, pp. 890-898
-
-
Jurczak, M.J.1
Lee, H-Y.2
Birkenfeld, A.L.3
-
44
-
-
12944331141
-
Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats
-
Yang BC, Brown KK, Chen LH, et al. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. BMC Pharmacol 2004; 18(4): 23.
-
(2004)
BMC Pharmacol
, vol.18
, Issue.4
, pp. 23
-
-
Yang, B.C.1
Brown, K.K.2
Chen, L.H.3
|